Table 1 Participant demographics and characteristics at baseline and following 20 weeks of treatment
From: The effect of metformin on influenza vaccine responses in nondiabetic older adults: a pilot trial
| Â | Placebo | Metformin |
|---|---|---|
Subjects | 7 | 8 |
Age | 74.71 ± 2.45 | 74.13 ± 2.42 |
Male | 3, 43% | 5, 63% |
Number Comorbidities Per Subject (#) | 2.57 ± 0.84 | 2.50 ± 0.65 |
Height (inches) | 64.43 ± 2.09 | 66.73 ± 1.13 |
Baseline Weight (lbs) | 159.43 ± 7.52 | 167.86 ± 12.23 |
End of Treatment Weight (lbs) | 162.71 ± 8.24 | 164.18 ± 13.09 |
Baseline BMI (kg/m2) | 27.31 ± 1.68 | 26.43 ± 1.47 |
End of Treatment BMI (kg/m2) | 27.83 ± 1.74 | 25.80 ± 1.56 |
Baseline Rockwood Frailty Index | 0.09 ± 0.007 | 0.08 ± 0.003 |
End of Treatment Rockwood Frailty Index | 0.09 ± .005 | 0.09 ± 0.005 |
Baseline Fried Frailty Score | 0.86 ± 0.26 | 0.75 ± 0.25 |
End of Treatment Fried Frailty Score | 1.29 ± 0.29 | 0.75 ± 0.16 |
Baseline SPPB Score | 11 ± 0.69 | 10.63 ± 0.71 |
End of Treatment SPPB Score | 11.43 ± 0.30 | 11.43 ± 0.28 |